If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label

ALWAYS DISPENSE WITH
MEDICATION GUIDE

Pfizer

NDC 0069-1001-01

Xeljanz®
(tofacitinib) tablets

5 mg*

60 Tablets
Rx only

PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label

PRINCIPAL DISPLAY PANEL - 11 mg Tablet Bottle Label

ALWAYS DISPENSE WITH
MEDICATION GUIDE

Pfizer

NDC 0069-0501-30

Xeljanz® XR
(tofacitinib) tablets

Extended Release Tablets

11 mg*

30 Tablets
Rx only

PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label

ALWAYS DISPENSE WITH
MEDICATION GUIDE

Pfizer

NDC 0069-1002-01

Xeljanz®
(tofacitinib) tablets

10 mg*

10mg Is Recommended Only In
Ulcerative Colitis

60 Tablets
Rx only

PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label

PRINCIPAL DISPLAY PANEL - 22 mg Tablet Bottle Label

ALWAYS DISPENSE WITH
MEDICATION GUIDE

Pfizer

NDC 0069-0502-30

Xeljanz® XR
(tofacitinib) tablets
Extended Release Tablets

22 mg*

22mg Is Recommended Only In
Ulcerative Colitis

30 Tablets
Rx only

PRINCIPAL DISPLAY PANEL - 22 mg Tablet Bottle Label

PRINCIPAL DISPLAY PANEL - 240 mL Bottle Label

NDC 0069-1029-01

ALWAYS DISPENSE WITH
MEDICATION GUIDE

Pfizer

Xeljanz®
(tofacitinib) oral solution

1 mg/mL

240 mL
Rx only

PRINCIPAL DISPLAY PANEL - 240 mL Bottle Label

PRINCIPAL DISPLAY PANEL - 240 mL Bottle Carton

NDC 0069-1029-02

ALWAYS DISPENSE WITH MEDICATION GUIDE

Pfizer

Xeljanz®
(tofacitinib) oral solution

1 mg/mL

Contents:

Oral solution bottle
1 Oral dosing syringe
1 Press-in bottle adapter
Prescribing Information
Medication Guide
Instructions for Use

240 mL
Rx only

PRINCIPAL DISPLAY PANEL - 240 mL Bottle Carton

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

XELJANZ / XELJANZ XR Quick Finder

Ingredient & Allergen Checker
Xeljanz Dear HCP Letter - December 2021
Pfizer samples (for eligible HCPs)

Requests for samples of prescription medications can be made by contacting Pfizer for Professionals at 1-800-505-4426 or by visiting the PfizerPro website www.pfizerpro.com.
Report an adverse event or concern about the quality of a Pfizer product

To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly by visiting www.fda.gov/medwatch or by calling (800)-332-1088.
Assistance programs (for eligible patients)

Pfizer RxPathways connects eligible patients to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. Patients and physicians can contact RxPathways at (866) 706-2400 or visit the website for more information on these programs www.pfizerrxpathways.com.
Resources

Show All Hide All